Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial

J. R. Mackey, T. Pieńkowski, J. Crown, S. Sadeghi, M. Martin, A. Chan, M. Saleh, S. Sehdev, L. Provencher, V. Semiglazov, M. F. Press, G. Sauter, M. Lindsay, V. Houé, M. Buyse, P. Drevot, S. Hitier, S. Bensfia, W. Eiermann

Research output: Contribution to journalArticlepeer-review

45 Citations (Scopus)

Abstract

Background: The optimal regimen for adjuvant breast cancer chemotherapy is undefined. We compared sequential to concurrent combination of doxorubicin and cyclophosphamide with docetaxel chemotherapy in women with nodepositive non-metastatic breast cancer. We report the final, 10-year analysis of disease-free survival (DFS), overall survival (OS), and long-term safety. Patients and methods: A total of 3298 women with HER2 nonamplified breast cancer were randomized to doxorubicin and cyclophosphamide every 3 weeks for four cycles followed by docetaxel (AC→T) every 3 weeks for four cycles or docetaxel, doxorubicin, and cyclophosphamide (TAC) every 3 weeks for six cycles. The patients received standard radiotherapy and endocrine therapy and were followed up for 10 years with annual clinical evaluation and mammography. Results: The 10-year DFS rates were 66.5% in the AC→T arm and 66.3% in the TAC arm (P = 0.749). OS was 79.9% in the AC→T arm and 78.9% in the TAC arm (P = 0.506). TAC was associated with higher rates of febrile neutropenia, although G-CSF primary prophylaxis greatly reduced this risk. AC→T was associated with a higher rate of myalgia, hand-foot syndrome, fluid retention, and sensory neuropathy. Conclusion: This 10-year analysis of the BCIRG-005 trial confirmed that the efficacy of TAC was not superior to AC→T in women with node-positive early breast cancer. The toxicity profiles differ between arms and were consistent with previous reports. The TAC regimen with G-CSF support provides shorter adjuvant treatment duration with less toxicity. Trial Registration: ClinicalTrials.gov Identifier NCT00312208.

Original languageEnglish
Pages (from-to)1041-1047
Number of pages7
JournalAnnals of Oncology
Volume27
Issue number6
DOIs
Publication statusPublished - 18 Jun 2016
Externally publishedYes

Keywords

  • Adjuvant chemotherapy
  • Cyclophosphamide
  • Docetaxel
  • Doxorubicin
  • Early stage breast cancer

Fingerprint

Dive into the research topics of 'Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial'. Together they form a unique fingerprint.

Cite this